$147.76
Value $365B
MRK and NRIX stock compared: price, dividend, valuation and results, from SEC filings.
$147.76
Value $365B
$15.48
Value $1.7B
Merck & Company (MRK) has a market value of $365B and Nurix Therapeutics (NRIX) $1.7B. Over the last year, with dividends, MRK moved +66.3% and NRIX +27.2%. The P/E is 148.9 for MRK and 5.7 for NRIX. Dividend yield: MRK 2.30%, NRIX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$365B
NRIX$1.7B
MRK is 216 times NRIX
Revenue, 12 months
MRK$67.4B
NRIX$702M
MRK is 96 times NRIX
Net income, 12 months
MRK$2.5B
NRIX$295M
MRK is 8.3 times NRIX
Operating margin
MRK–
NRIX41.3%
ROIC
MRK3.9%
NRIX41.4%
37.5 points apart
P/E
MRK148.9
NRIX5.7
MRK is 26 times NRIX
Dividend yield
MRK2.3%
NRIX0.0%
2.3 points apart
5-year return
MRK+104.9%
NRIX-54.6%
159.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+104.9%
NRIX-54.6%
| Period | MRKWith dividends | NRIXWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +66.3%Price +61.6% | +27.2%Price +27.2% |
| 3 years since November 13, 2023 | +58.0%+16.5% a yearPrice +44.2% | +194.3%+43.3% a yearPrice +194.3% |
| 5 years since November 12, 2021 | +104.9%+15.4% a yearPrice +75.9% | -54.6%-14.6% a yearPrice -54.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyNRIXNurix Therapeutics
| Price | $147.76 | $15.48 |
|---|---|---|
| Market value | $365B | $1.7B |
| Enterprise value (EV) | $409B | $591M |
| P/E | 148.9 | 5.7 |
| P/E, 5-year median | 14.8 | – |
| P/B | 8.1 | 1.8 |
| EV/EBIT | 86.0 | 2.0 |
| Free cash flow yield | 4.0% | 21.9% |
| Revenue, 12 months | $67.4B | $702M |
|---|---|---|
| Net income, 12 months | $2.5B | $295M |
| Free cash flow, 12 months | $14.7B | $370M |
| Earnings per share, 12 months | $0.98 | $2.70 |
| Revenue growth, year on year | 1.3% | 53.9% |
| Revenue growth a year, past | +9.4%over 5 years | +36.4%over 5 years |
| EPS growth a year, past | +21.2%over 5 years | – |
| Gross margin | 71.8% | – |
|---|---|---|
| Operating margin | – | 41.3% |
| Net margin | 3.6% | 42.0% |
| ROIC | 3.9% | 41.4% |
| ROE | 5.2% | 53.4% |
| Cash | $9.7B | $1.1B |
|---|---|---|
| Total debt | $53.8B | $65M |
| Net debt / EBITDA | 5.7 | -3.7 |
| Interest cover | 2.4× | – |
| Dividend yield | 2.3% | – |
|---|---|---|
| Dividend per share, 12 months | $3.40 | – |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.4% | – |
| Shareholder yield | 3.7% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($365B) is about 216.0 times Nurix Therapeutics ($1.7B), at today's prices.
Since November 12, 2021, MRK's price moved +75.9% and NRIX's -54.6%. With dividends: MRK +104.9% (+15.4% a year), NRIX -54.6% (-14.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.30% for Merck & Company and none for Nurix Therapeutics. Over the last twelve months they paid $3.40 and – per share.
At today's price, the P/E is 148.9 for MRK and 5.7 for NRIX. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 3.6% for Merck & Company and 42.0% for Nurix Therapeutics, and the operating margin – and 41.3%. Revenue was $67.4B and $702M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.